We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tumor Suppressor MicroRNA Blocks Cancer Growth in Model

By LabMedica International staff writers
Posted on 19 Dec 2018
By inducing the production of a tumor suppressing microRNA in immune system B-cells, cancer researchers were able to inhibit tumor growth in a mouse model system.

MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. More...
MiRNAs resemble siRNAs of the RNA interference (RNAi) pathway, except miRNAs derive from regions of RNA transcripts that fold back on themselves to form short hairpins, whereas siRNAs derive from longer regions of double-stranded RNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.

In the current study, which was published in the December 4, 2018, online edition of the journal Scientific Reports, investigators at the University of California, San Diego (USA) worked with the microRNA miR-335, which specifically inhibits the SOX4 transcription factor that promotes tumor growth.

To deliver miR-335 to tumor cells in a mouse model system, the investigators loaded B-cells growing in culture with a miR-335 precursor. The B-cells converted the precursor into mature, active miR-335 and packaged it into small, membrane-coated vesicles that budded off from the cell as induced extracellular vesicles (iEVs). Each B-cell was able to produce about 100,000 miR-335-containing vesicles per day.

The investigators demonstrated that iEVs-335 efficiently and durably restored the endogenous miR-335 pool in human triple negative breast cancer cells, downregulated the expression of the miR-335 target gene SOX4 transcription factor, and markedly inhibited tumor growth in vivo. For this study, human breast cancer cells growing in culture were treated with miR-335-containing vesicles or sham vesicles. The cancer cells were transplanted into mice. After 60 days, 100% (5/5) of the mice with mock-treated cancer cells had large tumors. In contrast, only 44% (4/9) of the mice with miR-335 vesicle-treated cancer cells had tumors. On average, the tumors in the treated mice were more than 260 times smaller than those in the mock-treated mice.

The iEVs-335 mediated transcriptional effects persisted in tumors for more than 60 days following implantation. Genome-wide RNASeq analysis of cancer cells treated in vitro with iEVs-335 showed the regulation of a discrete number of genes only, without broad disruption of the transcriptome.

"Once further developed, we envision this method could be used in situations where other forms of immunotherapy do not work," said senior author Dr. Maurizio Zanetti, professor of medicine at the University of California, San Diego. "The advantages are that this type of treatment is localized, meaning potentially fewer side effects. It is longlasting, so a patient might not need frequent injections or infusions. And it would likely work against a number of different tumor types, including breast cancer, ovarian cancer, gastric cancer, pancreatic cancer, and hepatocellular carcinoma."

"Ideally, in the future we could test patients to see if they carry a deficiency in miR-335 and have an overabundance of SOX4," said Dr. Zanetti. "Then we would treat only those patients, cases where we know the treatment would most likely work. That is what we call personalized, or precision, medicine. We could also apply this technique to other microRNAs with other targets in cancer cells and in other cell types that surround and enable tumors."

Related Links:
University of California, San Diego


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
ESR Analyzer
TEST1 2.0
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.